SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Bartsch C, Bartsch H, Bellmann O, Lippert TH. 1991. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 67: 16811684.
  • Bejarano I, Redondo PC, Espino J, Rosado JA, Paredes SD, Barriga C, Reiter RJ, Pariente JA, Rodriguez AB. 2009. Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. J Pineal Res 46: 392400.
  • Carbajo-Pescador S, Martin-Renedo J, Garcia-Palomo A, Tunon MJ, Mauriz JL, Gonzalez-Gallego J. 2009. Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells. J Pineal Res 47: 330338.
  • Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C, Sanchez-Barcelo EJ. 2006. Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett 235: 266271.
  • Crew KD, Neugut AI. 2006. Epidemiology of gastric cancer. World J Gastroenterol 12: 354362.
  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942949.
  • Enarsson K, Johnsson E, Lindholm C, Lundgren A, Pan-Hammarstrom Q, Stromberg E, Bergin P, Baunge EL, Svennerholm AM, Quiding-Jarbrink M. 2006. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin Immunol 118: 2434.
  • Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202: 919929.
  • Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 10571061.
  • Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. 2003. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 44044408.
  • Joo SS, Yoo YM. 2009. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 47: 814.
  • Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, Wu HY, Chen CC, Hsu LF. 2007. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 43: 389403.
  • Kos-Kudla B, Ostrowska Z, Kozlowski A, Marek B, Ciesielska-Kopacz N, Kudla M, Kajdaniuk D, Strzelczyk J, Staszewicz P. 2002. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuro Endocrinol Lett 23: 239242.
  • Lissoni P. 2007. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 55: 201204.
  • Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. 1989. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 25: 789795.
  • Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 27562761.
  • Martin V, Garcia-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Sanchez-Sanchez A, Antolin I, Medina M, Rodriguez C. Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. Cancer Lett 287: 216223.
  • Martinez-Campa CM, Alonso-Gonzalez C, Mediavilla MD, Cos S, Gonzalez A, Sanchez-Barcelo EJ. 2008. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 268: 272277.
  • Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. 2008. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 98: 148153.
  • Mocchegiani E, Perissin L, Santarelli L, Tibaldi A, Zorzet S, Rapozzi V, Giacconi R, Bulian D, Giraldi T. 1999. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int J Immunopharmacol 21: 2746.
  • Park JW, Hwang MS, Suh SI, Baek WK. 2009. Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 46: 415421.
  • Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F. 2008. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 44: 18751882.
  • Reiter RJ. 2004. Mechanisms of cancer inhibition by melatonin. J Pineal Res 37: 213214.
  • Reiter RJ, Tan DX, Erren TC, Fuentes-Broto L, Paredes SD. 2009. Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. Integr Cancer Ther 8: 354360.
  • Saez MC, Barriga C, Garcia JJ, Rodriguez AB, Masot J, Duran E, Ortega E. 2005. Melatonin increases the survival time of animals with untreated mammary tumours: neuroendocrine stabilization. Mol Cell Biochem 278: 1520.
  • Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. 2003. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60: 14071426.
  • Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. 2005. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63: 2943.
  • Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 11511164.
  • Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. 2008a. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7: 189203.
  • Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. 2008b. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 15: 93101.
  • Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. 2003. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63: 77247732.
  • Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. 2005. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41: 722730.
  • Wenzel U, Nickel A, Daniel H. 2005. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. Int J Cancer 116: 236242.
  • Yuan J, Yankner BA. 2000. Apoptosis in the nervous system. Nature 407: 802809.